Contact this trialFirst, we need to learn more about you.
Anti-mitotic agent
Alisertib for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Burnsville, Minnesota
This trial is studying how safe & effective alisertib is in treating patients with advanced small cell lung cancer after first-line treatment. They'll also look for biomarkers to identify subgroups who may benefit most.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service